Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 1263 entries
Sorted by: Best Match Show Resources per page
HBV Core Protein Enhances Cytokine Production.

Diseases (Basel, Switzerland)

Kanda T, Wu S, Sasaki R, Nakamura M, Haga Y, Jiang X, Nakamoto S, Yokosuka O.
PMID: 28943621
Diseases. 2015 Sep 17;3(3):213-220. doi: 10.3390/diseases3030213.

Hepatitis B virus (HBV) infection, a cause of hepatocellular carcinoma (HCC), remains a serious global health concern. HCC development and human hepatocarcinogenesis are associated with hepatic inflammation caused by host interferons and cytokines. This article focused on the association...

Cite
Kanda T, Wu S, Sasaki R, et al. HBV Core Protein Enhances Cytokine Production. Diseases. 2015;3(3):213-220doi: 10.3390/diseases3030213.
Kanda, T., Wu, S., Sasaki, R., Nakamura, M., Haga, Y., Jiang, X., Nakamoto, S., & Yokosuka, O. (2015). HBV Core Protein Enhances Cytokine Production. Diseases (Basel, Switzerland), 3(3), 213-220. https://doi.org/10.3390/diseases3030213
Kanda, Tatsuo, et al. "HBV Core Protein Enhances Cytokine Production." Diseases (Basel, Switzerland) vol. 3,3 (2015): 213-220. doi: https://doi.org/10.3390/diseases3030213
Kanda T, Wu S, Sasaki R, Nakamura M, Haga Y, Jiang X, Nakamoto S, Yokosuka O. HBV Core Protein Enhances Cytokine Production. Diseases. 2015 Sep 17;3(3):213-220. doi: 10.3390/diseases3030213. PMID: 28943621; PMCID: PMC5548245.
Copy Download .nbib Format: NLM
Interferons and HIV Infection: The Good, the Bad, and the Ugly.

Pathogens & immunity

Utay NS, Douek DC.
PMID: 27500281
Pathog Immun. 2016;1(1):107-116. doi: 10.20411/pai.v1i1.125.

Whether type I interferons (IFNs) hinder or facilitate HIV disease progression is controversial. Type I IFNs induce the production of restriction factors that protect against mucosal HIV/SIV acquisition and limit virus replication once systemic infection is established. However, type...

Cite
Utay NS, Douek DC. Interferons and HIV Infection: The Good, the Bad, and the Ugly. Pathog Immun. 2016;1(1):107-116doi: 10.20411/pai.v1i1.125.
Utay, N. S., & Douek, D. C. (2016). Interferons and HIV Infection: The Good, the Bad, and the Ugly. Pathogens & immunity, 1(1), 107-116. https://doi.org/10.20411/pai.v1i1.125
Utay, Netanya S, and Douek, Daniel C. "Interferons and HIV Infection: The Good, the Bad, and the Ugly." Pathogens & immunity vol. 1,1 (2016): 107-116. doi: https://doi.org/10.20411/pai.v1i1.125
Utay NS, Douek DC. Interferons and HIV Infection: The Good, the Bad, and the Ugly. Pathog Immun. 2016;1(1):107-116. doi: 10.20411/pai.v1i1.125. PMID: 27500281; PMCID: PMC4972494.
Copy Download .nbib Format: NLM
Proinflammatory response induced by Newcastle disease virus in tumor and normal cells.

Oncolytic virotherapy

Ginting TE, Suryatenggara J, Christian S, Mathew G.
PMID: 28293547
Oncolytic Virother. 2017 Mar 03;6:21-30. doi: 10.2147/OV.S123292. eCollection 2017.

PURPOSE: To investigate the specific role of immune responses induced by lentogenic Newcastle disease virus (NDV) for its antitumor effect.MATERIALS AND METHODS: NDV LaSota strain was used to infect the following human cells: non-small cell lung carcinoma (A549), glioblastoma...

Cite
Ginting TE, Suryatenggara J, Christian S, et al. Proinflammatory response induced by Newcastle disease virus in tumor and normal cells. Oncolytic Virother. 2017;6:21-30doi: 10.2147/OV.S123292.
Ginting, T. E., Suryatenggara, J., Christian, S., & Mathew, G. (2017). Proinflammatory response induced by Newcastle disease virus in tumor and normal cells. Oncolytic virotherapy, 621-30. https://doi.org/10.2147/OV.S123292
Ginting, Teridah Ernala, et al. "Proinflammatory response induced by Newcastle disease virus in tumor and normal cells." Oncolytic virotherapy vol. 6 (2017): 21-30. doi: https://doi.org/10.2147/OV.S123292
Ginting TE, Suryatenggara J, Christian S, Mathew G. Proinflammatory response induced by Newcastle disease virus in tumor and normal cells. Oncolytic Virother. 2017 Mar 03;6:21-30. doi: 10.2147/OV.S123292. eCollection 2017. PMID: 28293547; PMCID: PMC5345992.
Copy Download .nbib Format: NLM
Deciphering the role of DC subsets in MCMV infection to better understand immune protection against viral infections.

Frontiers in microbiology

Alexandre YO, Cocita CD, Ghilas S, Dalod M.
PMID: 25120535
Front Microbiol. 2014 Jul 29;5:378. doi: 10.3389/fmicb.2014.00378. eCollection 2014.

Infection of mice with murine cytomegalovirus (MCMV) recapitulates many physiopathological characteristics of human CMV infection and enables studying the interactions between a virus and its natural host. Dendritic cells (DC) are mononuclear phagocytes linking innate and adaptive immunity which...

Cite
Alexandre YO, Cocita CD, Ghilas S, et al. Deciphering the role of DC subsets in MCMV infection to better understand immune protection against viral infections. Front Microbiol. 2014;5:378doi: 10.3389/fmicb.2014.00378.
Alexandre, Y. O., Cocita, C. D., Ghilas, S., & Dalod, M. (2014). Deciphering the role of DC subsets in MCMV infection to better understand immune protection against viral infections. Frontiers in microbiology, 5378. https://doi.org/10.3389/fmicb.2014.00378
Alexandre, Yannick O, et al. "Deciphering the role of DC subsets in MCMV infection to better understand immune protection against viral infections." Frontiers in microbiology vol. 5 (2014): 378. doi: https://doi.org/10.3389/fmicb.2014.00378
Alexandre YO, Cocita CD, Ghilas S, Dalod M. Deciphering the role of DC subsets in MCMV infection to better understand immune protection against viral infections. Front Microbiol. 2014 Jul 29;5:378. doi: 10.3389/fmicb.2014.00378. eCollection 2014. PMID: 25120535; PMCID: PMC4114203.
Copy Download .nbib Format: NLM
Type I Interferons as Regulators of Lung Inflammation.

Frontiers in immunology

Makris S, Paulsen M, Johansson C.
PMID: 28344581
Front Immunol. 2017 Mar 10;8:259. doi: 10.3389/fimmu.2017.00259. eCollection 2017.

Immune responses to lung infections must be tightly regulated in order to permit pathogen eradication while maintaining organ function. Exuberant or dysregulated inflammation can impair gas exchange and underlies many instances of lung disease. An important driver of inflammation...

Cite
Makris S, Paulsen M, Johansson C. Type I Interferons as Regulators of Lung Inflammation. Front Immunol. 2017;8:259doi: 10.3389/fimmu.2017.00259.
Makris, S., Paulsen, M., & Johansson, C. (2017). Type I Interferons as Regulators of Lung Inflammation. Frontiers in immunology, 8259. https://doi.org/10.3389/fimmu.2017.00259
Makris, Spyridon, et al. "Type I Interferons as Regulators of Lung Inflammation." Frontiers in immunology vol. 8 (2017): 259. doi: https://doi.org/10.3389/fimmu.2017.00259
Makris S, Paulsen M, Johansson C. Type I Interferons as Regulators of Lung Inflammation. Front Immunol. 2017 Mar 10;8:259. doi: 10.3389/fimmu.2017.00259. eCollection 2017. PMID: 28344581; PMCID: PMC5344902.
Copy Download .nbib Format: NLM
Injectable therapy for Peyronie's disease.

Translational andrology and urology

Chong W, Tan RB.
PMID: 27298778
Transl Androl Urol. 2016 Jun;5(3):310-7. doi: 10.21037/tau.2016.03.15.

Peyronie's disease is a disfiguring and psychologically devastating disease, which continues to pose a significant clinical conundrum to the attending doctor. Many forms of therapy have been trialled but results have been inconsistent at best. Non-surgical therapy revolves around...

Cite
Chong W, Tan RB. Injectable therapy for Peyronie's disease. Transl Androl Urol. 2016;5(3):310-7doi: 10.21037/tau.2016.03.15.
Chong, W., & Tan, R. B. (2016). Injectable therapy for Peyronie's disease. Translational andrology and urology, 5(3), 310-7. https://doi.org/10.21037/tau.2016.03.15
Chong, Weiliang, and Tan, Ronny Ban Wei. "Injectable therapy for Peyronie's disease." Translational andrology and urology vol. 5,3 (2016): 310-7. doi: https://doi.org/10.21037/tau.2016.03.15
Chong W, Tan RB. Injectable therapy for Peyronie's disease. Transl Androl Urol. 2016 Jun;5(3):310-7. doi: 10.21037/tau.2016.03.15. PMID: 27298778; PMCID: PMC4893510.
Copy Download .nbib Format: NLM
Investigation by the Method of INNO-LiPA of Primary Resistance to Lamivudine in Patients with Chronic Hepatitis B Who Have Not Used Antiviral Therapy.

The West Indian medical journal

Özgüler M, Akbulut A, Demirdağ K, Özden M.
PMID: 26901602
West Indian Med J. 2015 Apr 30;65(1):111-115. doi: 10.7727/wimj.2014.291.

AIM: Two billion people around the world are exposed to the hepatitis B virus (HBV) and about 350 million are infected with chronic HBV. The infection can be acquired early (neonatal) and becomes chronic in 90%; this rate reduces...

Cite
Özgüler M, Akbulut A, Demirdağ K, et al. Investigation by the Method of INNO-LiPA of Primary Resistance to Lamivudine in Patients with Chronic Hepatitis B Who Have Not Used Antiviral Therapy. West Indian Med J. 2015;65(1):111-115doi: 10.7727/wimj.2014.291.
Özgüler, M., Akbulut, A., Demirdağ, K., & Özden, M. (2015). Investigation by the Method of INNO-LiPA of Primary Resistance to Lamivudine in Patients with Chronic Hepatitis B Who Have Not Used Antiviral Therapy. The West Indian medical journal, 65(1), 111-115. https://doi.org/10.7727/wimj.2014.291
Özgüler, M, et al. "Investigation by the Method of INNO-LiPA of Primary Resistance to Lamivudine in Patients with Chronic Hepatitis B Who Have Not Used Antiviral Therapy." The West Indian medical journal vol. 65,1 (2015): 111-115. doi: https://doi.org/10.7727/wimj.2014.291
Özgüler M, Akbulut A, Demirdağ K, Özden M. Investigation by the Method of INNO-LiPA of Primary Resistance to Lamivudine in Patients with Chronic Hepatitis B Who Have Not Used Antiviral Therapy. West Indian Med J. 2015 Apr 30;65(1):111-115. doi: 10.7727/wimj.2014.291. PMID: 26901602.
Copy Download .nbib Format: NLM
Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B.

Journal of clinical and translational hepatology

Zhang W, Zhang D, Dou X, Xie Q, Jiang J, Chen X, Ren H.
PMID: 29577026
J Clin Transl Hepatol. 2018 Mar 28;6(1):1-10. doi: 10.14218/JCTH.2017.00073. Epub 2018 Mar 17.

No abstract available.

Cite
Zhang W, Zhang D, Dou X, et al. Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B. J Clin Transl Hepatol. 2018;6(1):1-10doi: 10.14218/JCTH.2017.00073.
Zhang, W., Zhang, D., Dou, X., Xie, Q., Jiang, J., Chen, X., & Ren, H. (2018). Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B. Journal of clinical and translational hepatology, 6(1), 1-10. https://doi.org/10.14218/JCTH.2017.00073
Zhang, Wenhong, et al. "Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B." Journal of clinical and translational hepatology vol. 6,1 (2018): 1-10. doi: https://doi.org/10.14218/JCTH.2017.00073
Zhang W, Zhang D, Dou X, Xie Q, Jiang J, Chen X, Ren H. Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B. J Clin Transl Hepatol. 2018 Mar 28;6(1):1-10. doi: 10.14218/JCTH.2017.00073. Epub 2018 Mar 17. PMID: 29577026; PMCID: PMC5862993.
Copy Download .nbib Format: NLM
Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases.

Clinical pharmacology : advances and applications

Dreesen E, Bossuyt P, Mulleman D, Gils A, Pascual-Salcedo D.
PMID: 29042821
Clin Pharmacol. 2017 Oct 03;9:101-111. doi: 10.2147/CPAA.S138414. eCollection 2017.

Biopharmaceuticals directed against tumor necrosis factor-alpha, integrins, interleukins, interferons and their receptors have become key agents for the management of inflammatory diseases in the fields of gastroenterology, rheumatology, dermatology and neurology. However, response to these treatments is far from...

Cite
Dreesen E, Bossuyt P, Mulleman D, et al. Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases. Clin Pharmacol. 2017;9:101-111doi: 10.2147/CPAA.S138414.
Dreesen, E., Bossuyt, P., Mulleman, D., Gils, A., & Pascual-Salcedo, D. (2017). Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases. Clinical pharmacology : advances and applications, 9101-111. https://doi.org/10.2147/CPAA.S138414
Dreesen, Erwin, et al. "Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases." Clinical pharmacology : advances and applications vol. 9 (2017): 101-111. doi: https://doi.org/10.2147/CPAA.S138414
Dreesen E, Bossuyt P, Mulleman D, Gils A, Pascual-Salcedo D. Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases. Clin Pharmacol. 2017 Oct 03;9:101-111. doi: 10.2147/CPAA.S138414. eCollection 2017. PMID: 29042821; PMCID: PMC5633318.
Copy Download .nbib Format: NLM
Cell Polarization and Epigenetic Status Shape the Heterogeneous Response to Type III Interferons in Intestinal Epithelial Cells.

Frontiers in immunology

Bhushal S, Wolfsmüller M, Selvakumar TA, Kemper L, Wirth D, Hornef MW, Hauser H, Köster M.
PMID: 28659914
Front Immunol. 2017 Jun 12;8:671. doi: 10.3389/fimmu.2017.00671. eCollection 2017.

Type I and type III interferons (IFNs) are crucial components of the first-line antiviral host response. While specific receptors for both IFN types exist, intracellular signaling shares the same Jak-STAT pathway. Due to its receptor expression, IFN-λ responsiveness is...

Cite
Bhushal S, Wolfsmüller M, Selvakumar TA, et al. Cell Polarization and Epigenetic Status Shape the Heterogeneous Response to Type III Interferons in Intestinal Epithelial Cells. Front Immunol. 2017;8:671doi: 10.3389/fimmu.2017.00671.
Bhushal, S., Wolfsmüller, M., Selvakumar, T. A., Kemper, L., Wirth, D., Hornef, M. W., Hauser, H., & Köster, M. (2017). Cell Polarization and Epigenetic Status Shape the Heterogeneous Response to Type III Interferons in Intestinal Epithelial Cells. Frontiers in immunology, 8671. https://doi.org/10.3389/fimmu.2017.00671
Bhushal, Sudeep, et al. "Cell Polarization and Epigenetic Status Shape the Heterogeneous Response to Type III Interferons in Intestinal Epithelial Cells." Frontiers in immunology vol. 8 (2017): 671. doi: https://doi.org/10.3389/fimmu.2017.00671
Bhushal S, Wolfsmüller M, Selvakumar TA, Kemper L, Wirth D, Hornef MW, Hauser H, Köster M. Cell Polarization and Epigenetic Status Shape the Heterogeneous Response to Type III Interferons in Intestinal Epithelial Cells. Front Immunol. 2017 Jun 12;8:671. doi: 10.3389/fimmu.2017.00671. eCollection 2017. PMID: 28659914; PMCID: PMC5467006.
Copy Download .nbib Format: NLM
Tumor cell death by pattern-sensing of exogenous RNA: Tumor cell TLR3 directly induces necroptosis by poly(I:C) in vivo, independent of immune effector-mediated tumor shrinkage.

Oncoimmunology

Takaki H, Shime H, Matsumoto M, Seya T.
PMID: 29123946
Oncoimmunology. 2015 Dec 08;6(10):e1078968. doi: 10.1080/2162402X.2015.1078968. eCollection 2017.

Poly(I:C) acts on dendritic cells to induce potent antitumor effects through the production of cytokines/interferons, activation of natural killer cells and proliferation of cytotoxic T lymphocytes. In some tumor or myeloid lineages, poly(I:C) seemed to induce necroptosis in concert...

Cite
Takaki H, Shime H, Matsumoto M, et al. Tumor cell death by pattern-sensing of exogenous RNA: Tumor cell TLR3 directly induces necroptosis by poly(I:C) in vivo, independent of immune effector-mediated tumor shrinkage. Oncoimmunology. 2015;6(10):e1078968doi: 10.1080/2162402X.2015.1078968.
Takaki, H., Shime, H., Matsumoto, M., & Seya, T. (2017). Tumor cell death by pattern-sensing of exogenous RNA: Tumor cell TLR3 directly induces necroptosis by poly(I:C) in vivo, independent of immune effector-mediated tumor shrinkage. Oncoimmunology, 6(10), e1078968. https://doi.org/10.1080/2162402X.2015.1078968
Takaki, Hiromi, et al. "Tumor cell death by pattern-sensing of exogenous RNA: Tumor cell TLR3 directly induces necroptosis by poly(I:C) in vivo, independent of immune effector-mediated tumor shrinkage." Oncoimmunology vol. 6,10 (2017): e1078968. doi: https://doi.org/10.1080/2162402X.2015.1078968
Takaki H, Shime H, Matsumoto M, Seya T. Tumor cell death by pattern-sensing of exogenous RNA: Tumor cell TLR3 directly induces necroptosis by poly(I:C) in vivo, independent of immune effector-mediated tumor shrinkage. Oncoimmunology. 2015 Dec 08;6(10):e1078968. doi: 10.1080/2162402X.2015.1078968. eCollection 2017. PMID: 29123946; PMCID: PMC5665066.
Copy Download .nbib Format: NLM
Canonical and Non-Canonical Aspects of JAK-STAT Signaling: Lessons from Interferons for Cytokine Responses.

Frontiers in immunology

Majoros A, Platanitis E, Kernbauer-Hölzl E, Rosebrock F, Müller M, Decker T.
PMID: 28184222
Front Immunol. 2017 Jan 26;8:29. doi: 10.3389/fimmu.2017.00029. eCollection 2017.

Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signal transduction mediates cytokine responses. Canonical signaling is based on STAT tyrosine phosphorylation by activated JAKs. Downstream of interferon (IFN) receptors, activated JAKs cause the formation of the transcription factors...

Cite
Majoros A, Platanitis E, Kernbauer-Hölzl E, et al. Canonical and Non-Canonical Aspects of JAK-STAT Signaling: Lessons from Interferons for Cytokine Responses. Front Immunol. 2017;8:29doi: 10.3389/fimmu.2017.00029.
Majoros, A., Platanitis, E., Kernbauer-Hölzl, E., Rosebrock, F., Müller, M., & Decker, T. (2017). Canonical and Non-Canonical Aspects of JAK-STAT Signaling: Lessons from Interferons for Cytokine Responses. Frontiers in immunology, 829. https://doi.org/10.3389/fimmu.2017.00029
Majoros, Andrea, et al. "Canonical and Non-Canonical Aspects of JAK-STAT Signaling: Lessons from Interferons for Cytokine Responses." Frontiers in immunology vol. 8 (2017): 29. doi: https://doi.org/10.3389/fimmu.2017.00029
Majoros A, Platanitis E, Kernbauer-Hölzl E, Rosebrock F, Müller M, Decker T. Canonical and Non-Canonical Aspects of JAK-STAT Signaling: Lessons from Interferons for Cytokine Responses. Front Immunol. 2017 Jan 26;8:29. doi: 10.3389/fimmu.2017.00029. eCollection 2017. PMID: 28184222; PMCID: PMC5266721.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 1263 entries